Uncategorized

BioSystics, Inc. is planning Series A financing

(May 4, 2022) BioSystics, Inc., the company “accelerating the path to patient digital twins”, is seeking seed funding of up to $1.5M to hire senior management and to add to the technical staff for commercial growth after ten years of … Read More

BioSystics, Inc., a recent spin-off from the University of Pittsburgh is seeking Series A financing to accelerate the path to patient digital twins for the pharmaceutical and healthcare industries.

BioSystics, Inc., a recent spin-off from the University of Pittsburgh is seeking Series A financing to accelerate the path to patient digital twins for the pharmaceutical and healthcare industries. The BioSystics Analytics Platform™ (BioSystics-AP™) captures, analyzes, computationally models and shares … Read More

Hello from BioSystics!

Board Chairman Lans Taylor announced that BioSystics, Inc was incorporated on September 14, 2021 to commercialize the MPS Database. BioSystics will take over from the MPS Database Center the management and hosting of the current version of the MPS Database … Read More

BioSystics is to be a Silver sponsor of the MPS World Summit in 2022

BioSystics is proud to be a Silver sponsor of the MPS World Summit being held in New Orleans, May 31 – June 3, 2022.  At the meeting, we will be presenting the BioSystics Analytics platform, a platform for accessing, managing, … Read More

Funding from NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)…

CEO Mark Schurdak announced that NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) has provided funding to implement an iPSC portal to promote sharing of iPSCs among the MPSCoRe COVID-19 consortium members. Access to the portal will … Read More

Joint publication with Tissue Chip Validation Consortium at Texas A&M University (TAMU)

The MPS Database Center has jointly published a paper with the Tissuce Chip Validation Center at Texas A&M University (TAMU) that demonstrates the use of the MPS-Db for the analysis and reproducibility of the microphysiologyical systems. Sakolish C, Reese CE, … Read More

Funding from The National Center for Advancing Translational Sciences (NCATS)…

CEO Mark Schurdak announced that The National Center for Advancing Translational Sciences (NCATS) funding for the commercialization of the BioSystics Platform has been renewed through November 30, 2022.